Drug intelligence / Profile preview

recombinant fowlpox-NY-ESO-1

Development stage: Phase 2
Lead developer: Ludwig Cancer Research
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intradermal, Subcutaneous, Intramuscular

Overview

Recombinant fowlpox-NY-ESO-1 is a viral vector cancer vaccine consisting of a live-attenuated fowlpox virus engineered to express the cancer-testis antigen NY-ESO-1 (CTAG1B). Developed primarily by the Ludwig Institute for Cancer Research in collaboration with Therion Biologics, the vaccine is designed to stimulate a robust cellular immune response, including CD4+ and CD8+ T cells, against tumors that express NY-ESO-1, such as melanoma, ovarian cancer, and synovial sarcoma. It is frequently utilized in a heterologous prime-boost regimen, often following a priming dose with a recombinant vaccinia virus (rV-NY-ESO-1), to enhance the magnitude and breadth of the anti-tumor immune response while minimizing vector-specific immunity.

Other names: fowlpox-NY-ESO-1fowlpox-NY-ESO1fowlpox-NY-ESO 1rF-NY-ESO-1 vaccinerF-NY-ESO1 vaccinerF-NY-ESO 1 vaccinerecombinant fowlpox virus-NY-ESO-1

Targets

NY-ESO-1 (New york esophageal squamous cell carcinoma 1)

Beyond the preview

Go deeper on recombinant fowlpox-NY-ESO-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant fowlpox-NY-ESO-1.

Explore the full profile